Sept. 2016: Bristol-Myers Squibb (Stock to Study), MetLife (Undervalued)

The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Bristol-Myers Squibb Company (NYSE: BMY) as its September 2016 "Stock to Study" and MetLife, Inc. (NYSE: MET), as its September 2016 "Undervalued Stock" for investors' informational and educational use.

"The committee selected Bristol-Myers Squibb for its highly diversified product mix and growth opportunities for new products," said Adam Ritt, editor of BetterInvesting Magazine. "For the Undervalued selection, the committee believes MetLife's share price will benefit after several uncertainties facing the company are resolved."

Check BetterInvesting's September issue for more details about these selections. Go to the trial version of BetterInvesting's online tools to study the investment potential of Bristol-Myers Squibb and MetLife by viewing their fundamental data and applying judgments.

Committee members are Kenneth M. Bernard, CFA; Robert M. Bilkie, Jr., CFA; Daniel J. Boyle, CFA; Marisa Bradbury, CFA; Philip S. Dano, CFA; Donald E. Danko, CFA; Maury Elvekrog, CFA; and Walter J. Kirchberger, CFA.

As stated, the BetterInvesting committee's Stock to Study and Undervalued Stock choices are for the informational and educational uses of investors and are not intended as investment recommendations. BetterInvesting urges investors to educate themselves about the stock market so they can make informed decisions about stock purchases.
Sample Our Resources Open House Get Your Resources